- Home
- MURA vs ACCS Comparison
MURA vs ACCS Comparison
Compare MURA & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- ACCS
- Stock Information
- Founded
- MURA 2013
- ACCS 1988
- Country
- MURA Ireland
- ACCS United States
- Employees
- MURA N/A
- ACCS N/A
- Industry
- MURA
- ACCS Publishing
- Sector
- MURA
- ACCS Consumer Discretionary
- Exchange
- MURA Nasdaq
- ACCS Nasdaq
- Market Cap
- MURA 45.8M
- ACCS 44.2M
- IPO Year
- MURA N/A
- ACCS N/A
- Fundamental
- Price
- MURA $2.48
- ACCS $12.54
- Analyst Decision
- MURA Strong Buy
- ACCS Strong Buy
- Analyst Count
- MURA 3
- ACCS 1
- Target Price
- MURA $12.00
- ACCS $15.00
- AVG Volume (30 Days)
- MURA 100.7K
- ACCS 8.6K
- Earning Date
- MURA 08-12-2025
- ACCS 08-07-2025
- Dividend Yield
- MURA N/A
- ACCS N/A
- EPS Growth
- MURA N/A
- ACCS N/A
- EPS
- MURA N/A
- ACCS N/A
- Revenue
- MURA N/A
- ACCS $22,961,000.00
- Revenue This Year
- MURA N/A
- ACCS $7.67
- Revenue Next Year
- MURA N/A
- ACCS N/A
- P/E Ratio
- MURA N/A
- ACCS N/A
- Revenue Growth
- MURA N/A
- ACCS 6.92
- 52 Week Low
- MURA $0.95
- ACCS $7.71
- 52 Week High
- MURA $4.74
- ACCS $13.35
- Technical
- Relative Strength Index (RSI)
- MURA 45.72
- ACCS N/A
- Support Level
- MURA $2.41
- ACCS N/A
- Resistance Level
- MURA $2.55
- ACCS N/A
- Average True Range (ATR)
- MURA 0.09
- ACCS 0.00
- MACD
- MURA -0.01
- ACCS 0.00
- Stochastic Oscillator
- MURA 28.57
- ACCS 0.00
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.